S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
NASDAQ:ORIC

ORIC Pharmaceuticals - ORIC Stock Forecast, Price & News

$4.71
-0.13 (-2.69%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.57
$4.83
50-Day Range
$3.60
$5.24
52-Week Range
$2.62
$26.70
Volume
60,141 shs
Average Volume
441,939 shs
Market Capitalization
$185.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

ORIC Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
367.1% Upside
$22.00 Price Target
Short Interest
Bearish
9.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.95mentions of ORIC Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.44) to ($2.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

482nd out of 1,125 stocks

Pharmaceutical Preparations Industry

239th out of 554 stocks

ORIC stock logo

About ORIC Pharmaceuticals (NASDAQ:ORIC) Stock

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Analyst Ratings Changes

Several research firms recently issued reports on ORIC. Citigroup decreased their target price on shares of ORIC Pharmaceuticals to $9.00 and set a "buy" rating on the stock in a research report on Friday, May 20th. Oppenheimer began coverage on shares of ORIC Pharmaceuticals in a research report on Friday, July 15th. They issued a "hold" rating on the stock. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, ORIC Pharmaceuticals has an average rating of "Hold" and an average price target of $22.00.

ORIC Pharmaceuticals Stock Performance

NASDAQ:ORIC opened at $4.71 on Tuesday. ORIC Pharmaceuticals has a one year low of $2.62 and a one year high of $26.70. The company's 50 day moving average price is $4.31 and its 200 day moving average price is $5.15. The firm has a market capitalization of $185.94 million, a price-to-earnings ratio of -2.19 and a beta of 1.06.

Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORIC Stock News Headlines

Dr. Chudi Ndubaku joins Paraza Pharma as Chief Scientific Officer
Why ORIC Pharmaceuticals Shares Are Plunging Today
See More Headlines
Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORIC Company Calendar

Last Earnings
11/08/2021
Today
8/15/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORIC
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+367.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-78,710,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.93 per share

Miscellaneous

Free Float
37,127,000
Market Cap
$185.94 million
Optionable
Not Optionable
Beta
1.06

Key Executives

  • Dr. Richard A. Heyman Ph.D. (Age 65)
    Co-Founder, Independent Chairman & Member of Scientific Advisory Board
    Comp: $89.92k
  • Dr. Jacob M. Chacko M.B.A. (Age 43)
    M.D., Pres, CEO & Director
    Comp: $883.68k
  • Mr. Dominic G. Piscitelli CPA (Age 47)
    CPA, M.B.A., Chief Financial Officer
    Comp: $610.02k
  • Dr. Pratik S. Multani M.D. (Age 55)
    M.S., Chief Medical Officer
    Comp: $669.76k
  • Dr. Charles L. Sawyers B.A. (Age 63)
    BA, M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Scott W. Lowe Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Lori Sickels Friedman Ph.D. (Age 57)
    Chief Scientific Officer
  • Dr. Christian V. Kuhlen Esq. (Age 49)
    J.D., M.D., Gen. Counsel
  • Dr. Edna Chow Maneval (Age 62)
    Sr. VP of Clinical Devel.
  • Mr. Matthew Panuwat (Age 45)
    Chief Bus. Officer













ORIC Stock - Frequently Asked Questions

Should I buy or sell ORIC Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORIC, but not buy additional shares or sell existing shares.
View ORIC analyst ratings
or view top-rated stocks.

What is ORIC Pharmaceuticals' stock price forecast for 2022?

5 Wall Street analysts have issued 1-year target prices for ORIC Pharmaceuticals' shares. Their ORIC share price forecasts range from $9.00 to $31.00. On average, they expect the company's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 367.1% from the stock's current price.
View analysts price targets for ORIC
or view top-rated stocks among Wall Street analysts.

How have ORIC shares performed in 2022?

ORIC Pharmaceuticals' stock was trading at $14.70 at the beginning of 2022. Since then, ORIC shares have decreased by 68.0% and is now trading at $4.71.
View the best growth stocks for 2022 here
.

When is ORIC Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ORIC earnings forecast
.

How were ORIC Pharmaceuticals' earnings last quarter?

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) posted its quarterly earnings results on Monday, November, 8th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.11.

What other stocks do shareholders of ORIC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG).

When did ORIC Pharmaceuticals IPO?

(ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO.

What is ORIC Pharmaceuticals' stock symbol?

ORIC Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORIC."

Who are ORIC Pharmaceuticals' major shareholders?

ORIC Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (11.03%), Millennium Management LLC (3.65%), Silverarc Capital Management LLC (2.74%), Renaissance Technologies LLC (1.13%), Monaco Asset Management SAM (0.92%) and Northern Trust Corp (0.18%). Insiders that own company stock include Carl L Gordon, Dominic Piscitelli, Jacob Chacko, Orbimed Advisors Llc, Richard A Heyman, Richard A Heyman and Richard H Scheller.
View institutional ownership trends
.

How do I buy shares of ORIC Pharmaceuticals?

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ORIC Pharmaceuticals' stock price today?

One share of ORIC stock can currently be purchased for approximately $4.71.

How much money does ORIC Pharmaceuticals make?

ORIC Pharmaceuticals (NASDAQ:ORIC) has a market capitalization of $185.94 million. The company earns $-78,710,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

How can I contact ORIC Pharmaceuticals?

ORIC Pharmaceuticals' mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.oricpharma.com. The company can be reached via phone at 650-388-5600 or via email at investors@oricpharma.com.

This page (NASDAQ:ORIC) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.